scholarly journals Marine pharmacology in 2003–4: Marine compounds with anthelmintic antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action

Author(s):  
Alejandro M.S. Mayer ◽  
Abimael D. Rodríguez ◽  
Roberto G.S. Berlinck ◽  
Mark T. Hamann
Marine Drugs ◽  
2021 ◽  
Vol 19 (2) ◽  
pp. 49
Author(s):  
Alejandro M. S. Mayer ◽  
Aimee J. Guerrero ◽  
Abimael D. Rodríguez ◽  
Orazio Taglialatela-Scafati ◽  
Fumiaki Nakamura ◽  
...  

The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology reported by a growing number of investigators from 54 countries. The peer-reviewed literature reported antibacterial, antifungal, antiprotozoal, antituberculosis, and antiviral activities for 123 marine natural products, 111 marine compounds with antidiabetic and anti-inflammatory activities as well as affecting the immune and nervous system, while in contrast 79 marine compounds displayed miscellaneous mechanisms of action which upon further investigation may contribute to several pharmacological classes. Therefore, in 2016–2017, the preclinical marine natural product pharmacology pipeline generated both novel pharmacology as well as potentially new lead compounds for the growing clinical marine pharmaceutical pipeline, and thus sustained with its contributions the global research for novel and effective therapeutic strategies for multiple disease categories.


Marine Drugs ◽  
2019 ◽  
Vol 18 (1) ◽  
pp. 5 ◽  
Author(s):  
Alejandro M. S. Mayer ◽  
Aimee J. Guerrero ◽  
Abimael D. Rodríguez ◽  
Orazio Taglialatela-Scafati ◽  
Fumiaki Nakamura ◽  
...  

The systematic review of the marine pharmacology literature from 2014 to 2015 was completed in a manner consistent with the 1998–2013 reviews of this series. Research in marine pharmacology during 2014–2015, which was reported by investigators in 43 countries, described novel findings on the preclinical pharmacology of 301 marine compounds. These observations included antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic pharmacological activities for 133 marine natural products, 85 marine compounds with antidiabetic, and anti-inflammatory activities, as well as those that affected the immune and nervous system, and 83 marine compounds that displayed miscellaneous mechanisms of action, and may probably contribute to novel pharmacological classes upon further research. Thus, in 2014–2015, the preclinical marine natural product pharmacology pipeline provided novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, and thus continued to contribute to ongoing global research for alternative therapeutic approaches to many disease categories.


Sign in / Sign up

Export Citation Format

Share Document